Abstract

The aberrant activation of the phosphoinositide 3-kinase (PI3K) pathway is closely linked to the progression of various cancers, highlighting its significance as a target for cancer therapy. In contrast to conventional PI3K inhibitors, the selective degradation of PI3K protein via PROTAC technology presents a complementary therapeutic strategy. In this work, a 4-methylquinazoline based scaffold designed to bind to PI3K was conjugated with a CRBN ligand via an appropriate linker, leading to the discovery of a series of novel PI3K PROTAC degraders. Among them, degrader 12 was demonstrated to show selective degradation activity against PI3Kα, with a DC₅₀ value of 0.08 μM. In HGC-27 and T47D cancer cells, degrader 12 effectively degraded PI3Kα in a time- and concentration-dependent manner and potently inhibited the phosphorylation of AKT at the Ser473 site. Furthermore, with acceptable in vitro and in vivo pharmacokinetic properties, degrader 12 showed significant in vivo anticancer efficacy in HGC-27 and DOHH2 xenograft models.